Sir Peter MacCallum Department of Oncology, University of Melbourne Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia.
Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia; Centre for Health Policy, University of Melbourne, Melbourne, Victoria, Australia.
ESMO Open. 2020 Dec;5(6):e001090. doi: 10.1136/esmoopen-2020-001090.
To report clinician-perceived changes to cancer service delivery in response to COVID-19.
Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical Oncology.
Between May and June 2020 clinicians from 70 countries were surveyed; majority from Europe (n=196; 39%) with 1846 COVID-19 cases per million people, Australia (AUS)/New Zealand (NZ) (n=188; 38%) with 267/236 per million and Asia (n=75; 15%) with 121 per million at time of survey distribution.
Medical oncologists (n=372; 74%), radiation oncologists (n=91; 18%) and surgical oncologists (n=38; 8%).
Eighty-nine per cent of clinicians reported altering clinical practices; more commonly among those with versus without patients diagnosed with COVID-19 (n=142; 93% vs n=225; 86%, p=0.03) but regardless of community transmission levels (p=0.26). More European clinicians (n=111; 66.1%) had treated patients diagnosed with COVID-19 compared with Asia (n=20; 27.8%) and AUS/NZ (n=8; 4.8%), p<0.001. Many clinicians (n=307; 71.4%) reported concerns that reduced access to standard treatments during the pandemic would negatively impact patient survival. The reported proportion of consultations using telehealth increased by 7.7-fold, with 25.1% (n=108) of clinicians concerned that patient survival would be worse due to this increase. Clinicians reviewed a median of 10 fewer outpatients/week (including non-face to face) compared with prior to the pandemic, translating to 5010 fewer specialist oncology visits per week among the surveyed group. Mental health was negatively impacted for 52.6% (n=190) of clinicians.
Clinicians reported widespread changes to oncology services, in regions of both high and low COVID-19 case numbers. Clinician concerns of potential negative impacts on patient outcomes warrant objective assessment, with system and policy implications for healthcare delivery at large.
报告临床医生感知到的 COVID-19 对癌症服务提供的变化。
与欧洲肿瘤内科学会合作的多学科澳大拉西亚癌症临床医生调查。
2020 年 5 月至 6 月期间,来自 70 个国家的临床医生接受了调查;大多数来自欧洲(n=196;39%),每百万人中有 1846 例 COVID-19 病例,澳大利亚/新西兰(AUS/NZ)(n=188;38%)每百万人中有 267/236 例,亚洲(n=75;15%)每百万人中有 121 例。
医学肿瘤学家(n=372;74%)、放射肿瘤学家(n=91;18%)和外科肿瘤学家(n=38;8%)。
89%的临床医生报告改变了临床实践;在有和没有 COVID-19 诊断患者的临床医生中更为常见(n=142;93%与 n=225;86%,p=0.03),但与社区传播水平无关(p=0.26)。与亚洲(n=20;27.8%)和 AUS/NZ(n=8;4.8%)相比,更多的欧洲临床医生(n=111;66.1%)治疗过 COVID-19 诊断患者,p<0.001。许多临床医生(n=307;71.4%)报告说,担心大流行期间标准治疗的减少会对患者的生存产生负面影响。使用远程医疗的咨询比例增加了 7.7 倍,有 25.1%(n=108)的临床医生担心这一增加会导致患者的生存状况恶化。与大流行前相比,每周平均减少 10 名门诊病人/每周(包括非面对面),每周减少 5010 名专科肿瘤学就诊。52.6%(n=190)的临床医生的心理健康受到负面影响。
临床医生报告了肿瘤服务的广泛变化,在 COVID-19 病例数量高和低的地区都有变化。临床医生对潜在的对患者结局的负面影响的担忧需要客观评估,并对医疗保健的提供产生系统和政策影响。